Podocalyxin regulates astrocytoma cell invasion and survival against temozolomide

Experimental and Therapeutic Medicine

Volumn 5, Issue 4, 2013, Pages 1025-1029

  Wu, Hao ^a   Yang, Liang ^b   Liao, Daguang ^b   Chen, Yudan ^b   Wang, Wei ^c   Fang, Jiasheng ^a  

^a CENTRAL SOUTH UNIVERSITY   (China)

^b CENTRAL SOUTH UNIVERSITY   (China)

^c CENTRAL SOUTH UNIVERSITY   (China)

Author keywords

Astrocytoma; Cell survival; Chemoresistance; Glioblastoma; Invasion; Phosphatidylinositol 3 kinase Akt pathway; Podocalyxin; Temozolomide

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; GELATINASE B; PHOSPHATIDYLINOSITOL 3 KINASE; PODOCALYXIN; PROTEIN KINASE B; TEMOZOLOMIDE;

APOPTOSIS; ARTICLE; ASTROCYTOMA CELL; CELL INVASION; CELL SURVIVAL; CONTROLLED STUDY; GENE OVEREXPRESSION; GENE SILENCING; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MICROSCOPY; NICK END LABELING; PROTEIN PHOSPHORYLATION; UPREGULATION; VIRAL GENE DELIVERY SYSTEM; WESTERN BLOTTING;

EID: 84874640695     PISSN: 17920981     EISSN: 17921015     Source Type: Journal    
DOI: 10.3892/etm.2013.957     Document Type: Article

References (16)

1. Kleihues P, Burger PC, Collines VP, Newcomb EW, Ohagi H and Cavenee WK (eds): Astrocytic tumors. In: Glioblastoma. International Agency for Research on Cancer Press, Lyons, pp 29-39, 2000.
2. Giese A, Bjerkvig R, Berens ME and Westphal M: Cost of migration: invasion of malignant gliomas and implications for treatment. J Clin Oncol 21: 1624-1636, 2003.
3. Ohgaki H, Dessen P, Jourde B, et al: Genetic pathways to glioblastoma: a population-based study. Cancer Res 64: 6892-6899, 2004.
4. Reardon DA, Rich JN, Friedman HS and Bigner DD: Recent advances in the treatment of malignant astrocytoma. J Clin Oncol 24: 1253-1265, 2006.
5. Nielsen JS and McNagny KM: The role of podocalyxin in health and disease. J Am Soc Nephrol 20: 1669-1676, 2009.
6. Riccioni R, Calzolari A, Biffoni M, et al: Podocalyxin is expressed in normal and leukemic monocytes. Blood Cells Mol Dis 37: 218-225, 2006.
7. Yasuoka H, Tsujimoto M, Inagaki M, et al: Clinicopathological significance of podocalyxin and phosphorylated ezrin in uterine endometrioid adenocarcinoma. J Clin Pathol 65: 399-402, 2012.
8. Larsson A, Johansson ME, Wangefjord S, et al: Overexpression of podocalyxin-like protein is an independent factor of poor prognosis in colorectal cancer. Br J Cancer 105: 666-672, 2011.
9. Somasiri A, Nielsen JS, Makretsov N, et al: Overexpression of the anti-adhesin podocalyxin is an independent predictor of breast cancer progression. Cancer Res 64: 5068-5073, 2004.
10. Sizemore S, Cicek M, Sizemore N, Peng Ng K and Casey G: Podocalyxin increases the aggressive phenotype of breast and prostate cancer cells in vitro through its interaction with ezrin. Cancer Res 67: 6183-6191, 2007.
11. Hayatsu N, Kato Kaneko M, Mishima K, Nishikawa R, Matsutani M, Price JE and Kato Y: Podocalyxin expression in malignant astrocytic tumors. Biochem Biophys Res Commun 374: 394-398, 2008.
12. Hopkin K, Edwards P, Harris A, Klausner R, Peters G, Selby P and Stanley M: Cancer. In: Molecular Biology of the Cell. Alberts B, Johnson A, Lewis J, Martin R, Keith R and Peter W (eds). 4th edition. Garland Science, New York, pp1324-1325, 2002.
13. Favreau AJ, Cross EL and Sathyanarayana P: miR-199b-5p directly targets PODXL and DDR1 and decreased levels of miR-199b-5p correlate with elevated expressions of PODXL and DDR1 in acute myeloid leukemia. Am J Hematol 87: 442-446, 2012.
14. Hsu YH, Lin WL, Hou YT, et al: Podocalyxin EBP50 ezrin molecular complex enhances the metastatic potential of renal cell carcinoma through recruiting Rac1 guanine nucleotide exchange factor ARHGEF7. Am J Pathol 176: 3050-3061, 2010.
15. Khasraw M and Lassman AB: Advances in the treatment of malignant gliomas. Curr Oncol Rep 12: 26-33, 2010.
16. Borges KS, Castro-Gamero AM, Moreno DA, et al: Inhibition of Aurora kinases enhances chemosensitivity to temozolomide and causes radiosensitization in glioblastoma cells. J Cancer Res Clin Oncol 138: 405-414, 2012.